Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1056 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-29

Study Completion Date

2022-05-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to provide data on the proportion of seroconverted children and their immune status. It will also provide insight into the number of children currently infected at each time point including healthy carriers. Investigators will provide similar data on their parents in an ancillary study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children

NCT04490811

COVID-19

UNKNOWN

Seroprevalence of SARS-Cov-2 Antibodies in Children

NCT04347408

COVID Corona Virus Infection Multisystem Inflammatory Syndrome in Children

COMPLETED

COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants

NCT04413968

Coronavirus Coronavirus Infection Covid19 +1 more

COMPLETED NA

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

NCT04588363

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Multisystem Inflammatory Syndrome in Children (MIS-C) Coronavirus Disease 2019 (COVID-19)

COMPLETED

Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children

NCT04318431

Covid19

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The fraction of undiagnosed but likely to transmit the virus is a critical epidemiological characteristic that modulates the epidemic potential of SARS-CoV2. To adapt the epidemy control, it is essential to study the immunoprotection of the general population. A crucial question is the study of pauci or asymptomatic subjects, and in particular children who make mild forms, because they could act as a real reservoir for the spread of the virus. The serological study is essential in this context.

The serologic test Abbott will be used to study immunoprevalence. Institut Pasteur has validated test using neutralizing Ab. CEA will used a antibodies and antigen test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hospitalized children or consulting at hospital

Group Type EXPERIMENTAL

serology test

Intervention Type BIOLOGICAL

volume according to child weight

nasopharyngeal swab

Intervention Type BIOLOGICAL

nasopharyngeal swab for PCR

rectal swab

Intervention Type BIOLOGICAL

rectal swab for PCR

saliva sample

Intervention Type BIOLOGICAL

for biocollection

For hospitalized children or consulting at hospital

* any child over 7 days old and under 17 years old in consultation or hospitalized for at most 4 days at AP-HP or CH Cayenne; Or any child over 7 days old and under 17 years old with a positive PCR at home, with an attending physician in a participating centre
* Parent's agreement for blood, saliva and stool samples
* Optional parent's agreement for nasopharynx swab
* Optional parent's agreement for follow-up if PCR+
* With an Health insurance

For children with potential COVID disease during the first wave

* Any child over 7 days old and under 17 years, seropositive during the first wave
* Or any child over 7 days old and under 17 years, with a previous inflammatory clinical disease potentially linked to SARS-cov2
* With an Health insurance

Parent of the enrolled child

* One parent of the enrolled child on ped-covid
* Agreement for blood and saliva samples
* Optional agreement for nasopharynx swab
* Optional parent's agreement for follow-up if PCR+
* With an Health insurance

For children SARS-coV2 positive

* any child less then 18 years old
* infected by SARS-coV2
* Parent's agreement for blood, saliva samples
* Optional parent's agreement for nasopharynx swab
* With health insurance

For people living under the same roof of a child included in the study

* any child or adult living under the same roof of a child SARS-coV2 positive and included in the study
* With health insurance